Polydeoxyribonucleotide Injectables Market to Reach CGAR 16,3% by 2031 Top 20 Company Globally

Polydeoxyribonucleotide injectables are bio-molecular skin- and tissue-regenerative products derived most commonly from purified fish (salmon) DNA fragments; they are used in aesthetic medicine (skin boosters, post-procedure recovery), wound healing and certain regenerative applications. The active PDRN fragments act through adenosine receptor pathways to encourage angiogenesis, fibroblast activity and tissue repair, which has made them attractive both in medical dermatology and in the fast-growing minimally invasive aesthetic market. Recent clinical and review literature has reinforced PDRNs role in wound healing and dermal regeneration, supporting expanded clinical use and R&D into combination products and delivery systems.
The global Polydeoxyribonucleotide injectables market size for 2024 is USD 211 million, with an expected compound annual growth rate of 16.3% through 2031, reaching market size USD 608 million by 2031. The average selling price is USD 160 per unit, which implies global unit sales in 2024 of approximately 1,321,062 units. At a factory gross margin of 20%, the typical factory gross profit per unit is about USD 32, leaving an estimated cost of goods sold (COGS) per unit of USD 128. A COGS breakdown is: raw materials, processing/fill-finish, packaging, quality control, regulatory/compliance and logistics. A single line full machine production capacity is around 50,000 units per line per year. Downstream demand is concentrated in aesthetics followed by regenerative medicine and pharmaceutical.

Latest Trends and Technological Developments
The PDRN space is seeing several linked trends: broader clinical validation and peer-reviewed studies supporting regenerative claims (recent reviews and articles published in 2025 highlight new uses and formulations), growing industry activity in combination products that blend PDRN with hyaluronic acid or peptides, and investment in refined delivery systems (micro-aliquot injection protocols, hybrid HA-PDRN fillers). On June 2025 a market brief summarized accelerating demand for PDRN driven by aesthetics and wound-care adoption and named Asia-Pacific (South Korea, China, Japan) as a dominant region for commercialization and product launches. A 2025 clinical review and experimental papers documented promising results for HA-PDRN hybrids and new application techniques published in peer-reviewed journals (2025). Industry press in 2025 noted large commercial success stories from South Korean brands and an expanding private-label manufacturing ecosystem for PDRN skin boosters (news and industry reports, 2025). These developments indicate an active pipeline of product innovation and market expansion, particularly in Asia where regulatory pathways and clinic demand have historically allowed faster adoption of novel dermatologic injectables.
Revive Aesthetics Clinic, a prominent chain of medical aesthetic centers in Southern California, has signed an annual procurement agreement with Mastelli Srl, a leading Italian pharmaceutical company, for their flagship PDRN injectable product, Placentex®. Under the terms of the contract, Revive Aesthetics Clinic will purchase a total of 5,000 single-use 3ml vials of Placentex® annually, at a wholesale price of $45 per vial, amounting to a total contract value of $225,000. This bulk purchase is to support their expanding "Regenerative Skin Booster" treatment program, which has seen a 70% increase in patient demand over the last fiscal year.
The PDRN injectable is applied at Seoul Medi-Center, a renowned regenerative medicine hospital in South Korea, for the treatment of chronic rotator cuff tendinopathy. In their specialized protocol, physicians use a product like PN (Polydeoxyribonucleotide) from Regen Labs for ultrasound-guided percutaneous injections. For a standard treatment cycle, a patient receives three injections, each utilizing one 3ml vial of the PDRN solution. With the hospital's procurement cost at $50 per vial and a markup for procedure and professional fees, the total charged to the patient for the complete treatment cycle amounts to $900, demonstrating the high value and clinical application of the product in a real-world therapeutic setting.
Asia (especially South Korea, China and Japan) is the engine of PDRN injectables growth. South Korea remains a market and innovation leader: Korean companies and clinics pioneered many PDRN commercial products and professional protocols, and Korean brands and manufacturers dominate export flows and OEM private-labeling for skin boosters. China is a rapidly expanding market both for locally produced PDRN products and for imported brands, supported by high consumer demand for medical-grade aesthetics and strong clinic networks. Japan shows steady adoption in dermatology and skin repair sectors. Manufacturers, clinical trial activity and regulatory familiarity in these markets reduce time-to-market for new PDRN formulations, and regional manufacturing capability (API/extraction and fill-finish) supports scale-up. This Asia concentration is repeatedly highlighted in market analyses.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/sample/5277240

Polydeoxyribonucleotide Injectables by Type:
Single Ingredients Injectable

Combination Injectable

Polydeoxyribonucleotide Injectables by Type:
Salmon DNA Derived Polydeoxyribonucleotide

Synthetic / Recombinant Polydeoxyribonucleotide

Polydeoxyribonucleotide Injectables by Type:
Mecical Grade

Cosmetic Grade

Polydeoxyribonucleotide Injectables by Shape:
Liquid Injectable Solutions

Gel Type Injectables

Micro Encapsulated Formulations

Lyophilized Powder

Others

Polydeoxyribonucleotide Injectables by Size:
1 ml - 2 ml Dose Vial

3 ml - 5 ml Dose Vial

10 ml and Above dose Vial

Others

Polydeoxyribonucleotide Injectables by Application:
Aestethics

Skin Repair and Regeneration

Hydration and Texture Improvenement

Pigmentation Disorder

Others

Global Top 10 Key Companies in the Polydeoxyribonucleotide Injectables Market
ZK Medigroup Co Ltd.

BioPlus Co., Ltd

Pharma Research Products Co., Ltd

K Private Label

TY Cosmetic

Dermax Co., Ltd

Otesaly

Singderm

Placentex

Zerone Cellvane

HTL Biotechnology

Mastelli S.r.l

PolyBioSkin

GenoTech Corp.

Regen Lab

Humedix Co., Ltd

Dongkook NewPharm

MTC Co., Ltd

ReaLi Tide Biological Technology

Shandong Eledeep Bio Tech

Regional Insights
Within Southeast Asia, demand is strongest in advanced medical-aesthetic hubs (Singapore, Thailand) and is expanding rapidly in Indonesia, Malaysia, Philippines and Vietnam. Indonesia is notable for a large and fast-growing private aesthetic clinic market and rising medical tourism, which supports both imported PDRN products and local distribution partnerships; price sensitivity in some ASEAN markets encourages the growth of private-label offerings and multi-ingredient boosters that combine PDRN with HA or peptides. ASEAN market expansion is driven by more clinics adopting minimally invasive regenerative protocols, wider availability of trained injectors, and increasing consumer willingness to pay for clinically backed treatments. Regulatory regimes vary across ASEAN, so companies often pursue distributor partnerships or local registration pathways to accelerate entry. Industry press and market reports identify ASEAN as a high-growth regional corridor for Korean and Chinese PDRN brands.
Despite the momentum, PDRN injectables face several constraints: regulatory asymmetry across major markets (injectable approvals differ by jurisdiction, limiting immediate global rollout), inconsistent product standardization and variable labeling between PN (polynucleotide) and PDRN offerings which can confuse clinicians and buyers, supply-chain sensitivity tied to biological raw material sourcing and purification, and price-competitiveness pressure from lower-cost private labels. Clinical skepticism in some regions (and the need for higher-quality randomized controlled trials for certain indications) can slow adoption in conservative hospital settings. Finally, aseptic fill-finish capacity and quality certifications (GMP/GSP) are gating factors for scale-up, and achieving consistent batch-to-batch purity remains technically demanding.
For manufacturers and investors, winning strategies include securing high-purity raw material sources and patented extraction/refinement methods, investing in GMP aseptic fill-finish capacity or CDMO partnerships to assure supply, developing combination products (PDRN + HA/peptides) that meet clinic demand for multi-benefit boosters, and pursuing regulatory clearance in target export markets while building distributor networks in ASEAN. Clinical education and KOL (key opinion leader) programs in dermatologist and plastic surgeon communities accelerate uptake. Pricing strategy should balance clinic margins vs. unit volume: in price-sensitive ASEAN markets, private-label and bundled offerings often win share; in premium clinics (Korea, Singapore, urban China) brand and proven clinical data command higher ASPs. Recent M&A and private-label manufacturer listings indicate active consolidation and partnership opportunities in 20242025.

Product Models
Polydeoxyribonucleotide injectables are advanced biotechnological formulations derived from salmon DNA, used for regenerative medicine, dermatology, and aesthetic applications. These injectables promote tissue repair, improve skin elasticity, and enhance cell regeneration through activation of the A2A adenosine receptor pathway.
Single Ingredient Injectable: Contains only PDRN as the main active substance for targeted tissue regeneration and anti-aging therapy. Notable products include:
Placentex Integro Mastelli S.r.l.: A PDRN-based injectable for wound healing and post-surgical tissue recovery.
Rejuvenex PharmaResearch Products Co., Ltd.: Targets skin elasticity and firmness through DNA-based regeneration.
Rejuran I PharmaResearch Products Co., Ltd.: PDRN plus HA blend designed for delicate eye area rejuvenation.

Nucleofill Soft Plus Promoitalia Group S.p.A.: A gentle PDRN-based biostimulator with HA for hydration and revitalization.

Cellvane PDRN Zerone Cellvane (Korea): High-purity DNA-based injectable promoting fibroblast proliferation and collagen growth.
Combination Injectable: Combines PDRN with other synergistic agents (e.g., HA, niacinamide, peptides) to improve hydration, elasticity, and skin metabolism. Examples include:
Rejuran HB PharmaResearch Products Co., Ltd.: Combines PDRN with hyaluronic acid for deep hydration and regeneration.
Dermaheal PDRN Plus Caregen Co., Ltd.: PDRN with growth factors and vitamins to enhance collagen production.
Nucleospire Repair PharmaResearch Products Co., Ltd.: PDRN + peptide complex promoting long-term dermal restoration.

PDRN injectables represent a technically differentiated and fast-growing segment of regenerative aesthetic and wound-care products, with Asia (especially South Korea and China) leading both innovation and market adoption. The combination of favorable clinical literature, proven clinic demand for regenerative solutions, and increasing private-label and OEM manufacturing capacity supports a robust market outlook. Key risks include regulatory fragmentation, raw-material supply and the need for continued high-quality clinical evidence to broaden hospital and international adoption.

Investor Analysis
What investors should note: (1) a clearly defined addressable market (USD 211M in 2024, high-teens CAGR), (2) predictable unit economics (USD 160 ASP, ~USD 32 factory gross profit per unit at 20% margin), (3) concentrated regional leadership (APAC) that shortens routes to scale, and (4) clear levers for margin improvement (vertical integration in raw material/ purification or higher-value combination products). How to act: prioritize investments in companies with proven GMP manufacturing or CDMO partnerships, protect or acquire proprietary extraction/purification technologies, and fund clinical trials for new indications or combination formulations that unlock higher ASPs. Why it matters: the product category sits at the intersection of high consumer willingness to pay (aesthetics), increasing clinical acceptance (wound healing/regenerative medicine), and scalable manufacturing advances creating multiple exit pathways (strategic M&A by larger dermato-cosmetic firms, distribution rollouts across ASEAN, or licensing deals). The sectors strong regional momentum in Asia offers faster revenue ramp opportunities than many western-centric biologic niches, but investors should price regulatory and supply risks into valuations.
Request for Pre-Order Enquiry On This Report
https://www.qyresearch.com/customize/5277240

5 Reasons to Buy This Report
It quantifies the 2024 market size and provides a CAGR projection to guide valuation and revenue modeling.
It provides unit-level economics that enable per-unit margin analysis.
It highlights regional demand dynamics in Asia and ASEAN enabling targeted go-to-market and distribution planning.
It compiles the latest industry trends, clinical developments and dated news items (20242025) that affect regulatory and commercialization timelines.
It identifies leading players and strategic value levers (manufacturing, private-label, combination products) to support M&A or partnership decisions.
5 Key Questions Answered
What was the 2024 global market size and what CAGR should investors use for forecasts?
How many product units were sold globally in 2024 and what is the implied ASP and per-unit factory economics?
Which countries/regions are driving adoption and how does ASEAN fit into demand patterns?
What are the main manufacturing and supply-chain cost drivers (COGS breakdown and capacity constraints)?
Who are the principal competitors and what strategic moves (e.g., combination products, private-labeling, CDMO partnerships) are shaping the competitive landscape?
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of the product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Sales, revenue of the product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.

Related Report Recommendation

Global Polydeoxyribonucleotide Injectables Market Research Report 2025
https://www.qyresearch.com/reports/5277240/polydeoxyribonucleotide-injectables
Polydeoxyribonucleotide Injectables - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
https://www.qyresearch.com/reports/5277239/polydeoxyribonucleotide-injectables
Global Polydeoxyribonucleotide Injectables Market Outlook, InDepth Analysis & Forecast to 2031
https://www.qyresearch.com/reports/5277238/polydeoxyribonucleotide-injectables
Global Polydeoxyribonucleotide Injectables Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
https://www.qyresearch.com/reports/5277237/polydeoxyribonucleotide-injectables
Global Polydeoxyribonudeotide (PDRN) Market Research Report 2025
https://www.qyresearch.com/reports/3524744/polydeoxyribonudeotide--pdrn
Global Cosmetic Grade Polydeoxyribonudeotide (PDRN) Market Research Report 2025
https://www.qyresearch.com/reports/3799296/cosmetic-grade-polydeoxyribonudeotide--pdrn
Global Medical Grade Polydeoxyribonucleotide (PDRN) Market Research Report 2025
https://www.qyresearch.com/reports/4500811/medical-grade-polydeoxyribonucleotide--pdrn
Global Polydeoxyriboneucleotide(PDRN) Filler Market Research Report 2025
https://www.qyresearch.com/reports/4610028/polydeoxyriboneucleotide-pdrn--filler
Global PN/PDRN Dermal Fillers Market Research Report 2025
https://www.qyresearch.com/reports/4915324/pn-pdrn-dermal-fillers
Global Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) Market Research Report 2025
https://www.qyresearch.com/reports/4500816/polydeoxyribonucleotide--pdrn--and-polynucleotide--pn

Contact Information:
Tel: +1 626 2952 442 (US) ; +86-1082945717 (China)
+62 896 3769 3166 (Whatsapp)
Email: willyanto@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com

About QY Research
QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.
Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.
We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.
More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

This release was published on openPR.